The core of Martin’s endeavor lies in addressing a fundamental gap long overlooked in public health surveillance: the nuanced and evolving intervention preferences of people who use drugs. Historically, data guiding health responses have lacked localized insight into community priorities and behaviors, an absence that has hindered the tailoring of effective programs at the local level. By integrating community perspectives into an AI framework, the initiative—named AMPLIFY—seeks to “amplify” the voices of people who use drugs, ensuring their lived experiences and preferences directly inform the design and deployment of prevention and treatment interventions.

NIDA’s Avant-Garde Award is selectively granted each year to only a few exceptional scientists demonstrating creative boldness and possessing visionary ideas capable of opening wholly new frontiers in research. Dr. Martin’s project epitomizes this spirit, pioneering the use of AI to create dynamic, personalized digital twins. These are AI-generated simulations that embody the intervention decision-making patterns and preferences of individuals who use drugs, grounded in extensive cohort data and community engaged methodologies. This novel application of AI stands poised to significantly advance epidemic modeling by incorporating behavioral variables that have previously been difficult to quantify.

At present, despite substantial advances in biomedical prevention and long-acting antiretroviral therapies for HIV, the United States faces ongoing challenges in curbing HIV, HCV, and overdose among drug-using populations. A major barrier has been the lack of timely, granular data on the behaviors and needs of communities, especially in under-resourced areas with limited surveillance infrastructure. Dr. Martin’s approach aims to fill this gap by training large language models on comprehensive datasets, enabling the construction of realistic “digital twins” reflective of diverse demographic and geographic contexts. These digital twins then feed into sophisticated epidemiological models simulating transmission dynamics and health outcomes.

This integration of AI-powered digital simulations with traditional infectious disease models allows researchers to virtually test various prevention and treatment strategies in silico before real-world application. By modeling intervention impact and resource allocation at the community-specific level, public health officials can identify the most effective and cost-efficient strategies tailored to local needs. The capacity to experiment with diverse scenarios on a virtual platform represents a paradigm shift toward precision public health, focusing resources where they can yield the highest public health benefit.

Beyond immediate epidemic modeling, the use of AI to predict preferences and barriers among people who use drugs holds transformative potential for designing novel health service delivery models. It enables the identification of previously unrecognized obstacles to care, informs culturally and contextually competent intervention frameworks, and fosters adaptive health systems responsive to the evolving landscape of substance use disorders. Dr. Martin highlights that these advances could ultimately improve engagement and retention in care, reduce health disparities, and promote more equitable access to life-saving treatments.

The foundation for this innovative project rests on years of intensive collaboration between UC San Diego researchers and public health departments, particularly through the Resilient Shield initiative — a Centers for Disease Control-supported outbreak analytics center co-led by Martin. This partnership has provided practical insights revealing that interventions successful in one locale often do not translate well elsewhere due to variations in local social norms, intervention acceptance, and underlying epidemiology. Such findings underscore the imperative for flexible, data-driven strategies tailored to the unique contexts of individual communities.

A pioneering feature of AMPLIFY is its deep commitment to community engagement and participatory research. People with lived experience of substance use will be integral collaborators, shaping the development, validation, and deployment of the AI-generated digital twins. This inclusive approach ensures that ethical considerations, trust-building, and safeguarding practices are incorporated from the outset. It counters skepticism about AI in public health by emphasizing transparency and responsiveness to community priorities, cultivating a model of co-created health innovation.

The deliverable outcome includes an interactive decision-support dashboard designed for use by public health officials. This real-time platform will visualize scenario analyses, prevention strategy evaluations, and resource allocation simulations. By leveraging this tool, health departments across the country will acquire unprecedented agility and precision in responding to rapidly evolving health threats among vulnerable populations. The dashboard’s predictive analytics will also facilitate proactive rather than reactive responses, optimizing the impact of constrained public health budgets.

Key collaborators on the project encompass a multidisciplinary team of experts from UC San Diego, featuring specialists in infectious diseases, epidemiology, computational modeling, and public health: Ravi Goyal, PhD; Eli Aronoff-Spencer, MD, PhD; Steffanie Strathdee, PhD; Annick Bórquez, PhD; Laramie Smith, PhD; Britt Skaathun, PhD; John Ayers, PhD; alongside Angela Bazzi, PhD, from the Herbert Wertheim School of Public Health and Human Longevity Science. This collective expertise converges to advance the ambitious vision of embedding AI-informed decision-making at the heart of public health strategies aimed at mitigating HIV, HCV, and overdose epidemics.

In summary, Dr. Natasha Martin’s Avant-Garde Award-winning project exemplifies a forward-thinking fusion of artificial intelligence, community engagement, and infectious disease modeling to transform public health interventions. By creating AI-driven digital twins that encapsulate the lived realities and intervention preferences of people who use drugs, this approach promises to deliver finely tuned, locally relevant solutions capable of saving lives and promoting health equity across the United States. The AMPLIFY initiative represents a powerful leap toward harnessing technology and human insight to combat some of the nation’s most persistent public health challenges.

Subject of Research: Development of AI-driven digital twins to enhance public health responses to HIV, Hepatitis C, and overdose among people who use drugs.

Article Title: UC San Diego Receives $5.6 Million NIH Avant-Garde Award to Deploy AI in Combating HIV, Hepatitis C, and Overdose Epidemics

News Publication Date: Not specified

Web References: https://mediasvc.eurekalert.org/Api/v1/Multimedia/5cc2d79e-6c40-46e0-a713-75eaef7246c9/Rendition/low-res/Content/Public

Image Credits: UC San Diego Health Sciences

Keywords: HIV, Hepatitis C, Artificial Intelligence, Digital Twins, Substance Use Disorder, Public Health, Overdose Prevention, Large Language Models, Epidemiological Modeling, Community Engagement, Precision Public Health, National Institute on Drug Abuse

Psilocybin, the psychoactive compound found in so-called “magic mushrooms,” has recently emerged from decades of prohibition into the spotlight of medical research due to its promising therapeutic potential. However, despite early-stage clinical trials demonstrating efficacy in treating conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD), the broader effects and safety profile of psilocybin in non-clinical, community-based applications remain largely underexplored. This new initiative aims to fill that gap by measuring how legal access to psilocybin services impacts individuals across diverse populations, particularly focusing on those with substance use disorders.

The research arrives at a time when Oregon has become the first state in the United States to implement a state-regulated system allowing adults aged 21 and older to access supervised psilocybin sessions legally. This milestone followed a 2020 voter-approved ballot initiative, making Oregon a unique natural laboratory to evaluate psilocybin’s broader societal and health impacts. Colorado has also recently followed Oregon’s example by legalizing similar services, indicating a growing trend toward normalization and regulatory acceptance of psychedelic therapies.

Central to the study is the Oregon Psychedelic Evaluation Nexus (OPEN), a collaborative network co-directed by Dr. Adie Rae and Dr. Todd Korthuis. OPEN will recruit a large cohort of research participants—targeting over 1,600 individuals among the estimated 15,000 who have availed themselves of Oregon’s psilocybin program since its inception. Participants will complete longitudinal assessments via surveys and interviews at multiple intervals over 12 months following their initial psilocybin experience. This design enables the researchers to capture detailed, nuanced data on safety outcomes, efficacy across various substances, and individual differences in response to treatment.

The study is uniquely positioned to investigate psilocybin’s effects on substance use disorders, an area with scant rigorous data despite burgeoning anecdotal and clinical interest. Current evidence suggests psychedelics may contribute to reductions in tobacco and alcohol consumption, yet precise mechanisms, risk factors, and long-term outcomes are understudied. Dr. Rae highlights the necessity of methodical research to elucidate these dynamics, aiming to provide empirically grounded guidance for clinicians, policymakers, and patients. Taking a data-driven approach promises to demystify psilocybin’s therapeutic potential and limitations, mitigating polarized public opinions often driven more by ideology than evidence.

OHSU’s involvement underscores the importance of integrating addiction medicine expertise into psychedelic research. Dr. Korthuis, an addiction medicine specialist, emphasizes the importance of understanding psilocybin’s real-world usage patterns and efficacy compared to traditional interventions. He notes preliminary indications that some individuals are already utilizing psilocybin sessions in Oregon as a method to manage or reduce their substance use, highlighting the urgent need for systematic evaluation to ensure safety and inform best practices.

This initiative also builds on recent advancements in establishing standardized quality metrics for psilocybin services. A 2024 OHSU-led publication outlined 22 essential criteria for high-quality psychedelic care, derived from extensive interviews with experts ranging from clinical trial leaders to indigenous practitioners. These benchmarks are critical for assuring that psilocybin programs operate within frameworks that maximize therapeutic benefits while minimizing potential harms, thereby strengthening scientific rigor and consumer protections in this fast-evolving field.

While psilocybin is still classified federally as a Schedule I substance along with heroin and cannabis, its regulatory landscape is shifting. Researchers anticipate more states may replicate Oregon’s model, potentially heralding a new era where psilocybin becomes an accepted component of mental health and addiction treatment. Dr. Rae compares this prospective trajectory to that of acupuncture, which, though initially considered alternative medicine, gained mainstream acceptance through accumulating evidence demonstrating clinical and economic benefits.

Not everyone will respond to psilocybin, and experts caution against oversimplified narratives that frame psychedelics as panaceas. Nonetheless, this study aims to rigorously characterize who is most likely to benefit, identify specific substances that psilocybin may effectively target, and document any challenging psychological experiences that participants may encounter. Such comprehensive data collection is unprecedented outside of tightly controlled clinical trials and is essential for crafting evidence-based policies and clinical guidelines.

President of OHSU, Dr. Shereef Elnahal, underscores the transformative potential of this research, positioning Oregon’s regulated psilocybin program as an experimental platform for understanding therapeutic psychedelics at scale. By producing robust empirical data on both benefits and risks, the study hopes to illuminate the nuanced realities of psilocybin use beyond anecdote and hype, ultimately fostering informed public discourse and regulatory decision-making.

Already, preliminary data from over 300 clients within Oregon’s psilocybin service network have been gathered, providing early insights into user experiences and treatment patterns. The ongoing longitudinal study aims to expand these numbers significantly while maintaining rigorous methodological standards, marking a watershed moment in the scientific validation of psychedelic medicine. The findings are expected to hold relevance for clinicians, regulators, and patients alike, offering a critical evidence base as psychedelic-assisted therapies continue to evolve.

In sum, this federally supported research project represents a monumental step toward unraveling the complex interplay of psilocybin’s therapeutic potential and public health implications within legalized frameworks. By systematically assessing outcomes over an extended period and across diverse populations, the initiative promises to shape the future of psychedelic medicine, illuminating pathways to safer, more effective treatments for mental health and substance use disorders.

Subject of Research: Evaluation of the Safety and Effectiveness of State-Regulated Psilocybin Access, with a Focus on Substance Use Disorders

Article Title: Federal Study to Assess Real-World Impact of Legal Psilocybin Services in Oregon

News Publication Date: Not explicitly provided; inferred as June 2024 based on referenced sources

Web References:

• Oregon Psychedelic Evaluation Nexus (OPEN) – https://openpsychedelicscience.org/
• Oregon Psilocybin Services – https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx
• OHSU News Article on Psilocybin Research – https://news.ohsu.edu/2024/06/19/new-study-establishes-best-practices-for-supervised-psilocybin

References: National Institute on Drug Abuse, National Institutes of Health award R01DA060253

Keywords: Mushrooms, Substance related disorders, Mental health

The criminal legal system in the United States—comprising police stations, courts, jails, prisons, halfway houses, and community supervision settings—hosts millions of individuals affected by substance use disorders. Yet, the clinical and economic complexities of delivering effective treatment in these heterogeneous and resource-constrained environments remain underexplored. Historically, incarcerated individuals have often faced abrupt discontinuation of substance use treatments upon entry, triggering untreated withdrawal syndromes and a cascade of adverse health outcomes, including a devastating spike in overdose risk post-release.

This new grant underpins the establishment of the Criminal-Legal Economic Analysis & Resource (CLEAR) Center, which will operate within the broader framework of the Justice Community Overdose Innovation Network (JCOIN-II), an initiative dedicated to developing empirically validated, system-wide solutions for substance use disorder care integrated into criminal justice settings. Since its launch in 2019, JCOIN has focused on bridging gaps between clinical research and real-world implementation in notoriously fragmented correctional environments, striving to initiate treatment from incarceration through community reintegration.

Dr. Sean Murphy, professor in the department of population health sciences at Weill Cornell Medicine and one of the CLEAR Center’s co-principal investigators, emphasized the transformative potential of rigorous economic analyses. “CLEAR’s mission is not only to identify which interventions offer the best health outcomes but also to elucidate their economic viability, equipping policymakers and administrators with actionable tools to optimize budget allocation amidst chronic fiscal restraints,” Dr. Murphy explained.

Co-leading the initiative, Dr. Kathryn McCollister, professor and interim chair of public health sciences at the University of Miami’s Miller School of Medicine, brings extensive expertise in health economics methodology. Together, they aim to generate nuanced cost-effectiveness evaluations across a spectrum of clinical trials targeting substance use disorders, providing critical insights into designing scalable, sustainable programs within criminal-legal settings.

The complexity of the U.S. criminal legal system arises from its disparate institutional components, each operating with distinct budgetary realities, staffing structures, and regulatory constraints. This fragmentation historically obstructs the consistent delivery of evidence-based treatments, which are critical given the heightened vulnerability to relapse and overdose that individuals face immediately following release from incarceration. Effective intervention strategies must therefore be comprehensive and seamlessly integrated throughout all system phases.

The CLEAR Center’s analytical framework will incorporate the development of sophisticated decision-support tools, including cost-benefit analyses and budget-impact models, to facilitate strategic planning by criminal justice administrators and treatment providers. Such instruments will enable stakeholders to evaluate financial implications in the context of clinical efficacy, allowing for optimized resource deployment to maximize population-level health benefits.

Moreover, the CLEAR team will provide ongoing consultation and technical assistance to JCOIN-II clinical trials, ensuring that economic endpoints are robustly embedded into study designs. This interdisciplinary approach supports the translation of trial outcomes into practical guidelines for large-scale implementation, addressing a critical gap between research evidence and criminal justice policy execution.

Drs. Murphy and McCollister bring a strong foundation in substance use disorder health economics through their leadership roles within CHERISH, a NIDA-funded center of excellence focused on intersectional epidemics of addiction, HIV, and hepatitis C. Their collaboration within CHERISH, which recently received a renewed five-year, $10.9 million grant, underscores their capacity to conduct rigorous, policy-relevant health economic research at the nexus of complex infectious diseases and substance use.

This latest funding signals a commitment to confronting not only the biomedical challenges of addiction in incarcerated populations but also the economic and systemic barriers that hinder effective care delivery. By quantifying the value of evidence-based interventions within the fiscal realities of criminal justice agencies, the CLEAR Center aspires to catalyze a paradigm shift in how substance use disorders are addressed in these high-need populations.

The ultimate goal is to achieve sustained health improvements by rapidly initiating treatment upon incarceration and ensuring continuity of care immediately upon release—critical junctures where the risk of overdose and mortality surges dramatically. Through rigorous economic evaluation, CLEAR’s outputs will provide the empirical foundation necessary for advocating investment in interventions that demonstrate clear cost-effectiveness and public health impact.

As the opioid epidemic and other substance use crises continue to devastate communities, this innovative fusion of health economics and justice system reform represents a pivotal step toward deploying limited resources more strategically. The integration of economic insights into clinical and policy decision-making holds promise for mitigating overdose deaths and improving long-term recovery outcomes for individuals entangled in the criminal legal system.

In summary, the CLEAR Center, fortified by this new NIDA grant, will pioneer the generation and dissemination of robust economic evidence on substance use disorder interventions tailored to the unique context of the U.S. criminal justice system. Its success will depend on delivering pragmatic, actionable analyses that align with both clinical efficacy and budgetary feasibility, thus empowering decision-makers to enact sustainable, impactful reforms in addiction treatment services.

Subject of Research: Health economics of substance use disorder treatments and overdose prevention strategies within the criminal legal system.

Article Title: Not provided.

News Publication Date: Not provided.

Web References:

• Weill Cornell Medicine Sean Murphy profile
• University of Miami Kathryn McCollister profile
• CHERISH Renewal News

References:

• Link to the JAMA Network Open article on inadequacy of interventions
• Link to The Lancet article on post-release overdose risk

Image Credits: Not provided.

Keywords: Substance abuse, Substance related disorders, Behavioral psychology, Health economics, Criminal justice system, Substance use disorder, Overdose prevention, Cost-effectiveness, Population health sciences